Imagine trying to guess which patients need frequent hospital visits and which don't, but currently, everyone gets the same intense check-ups. This project uses a special brush to collect cells and analyzes their genetics to tell exactly who is at high risk of cancer returning. It's like moving from a one-size-fits-all schedule to a personalized alarm system for doctors.
Current surveillance for early esophageal cancer is inefficient, leading to over-treatment of most patients and under-treatment of the 30% who recur. This results in high healthcare costs and poor patient quality of life.
A biomarker-based risk stratification model and e-clinical tools for patient monitoring, supported by a health-economic model.
If you are a diagnostic kit manufacturer dealing with a lack of specific tools for Barrett's esophagus monitoring — this project developed a biomarker-based risk stratification model that allows for personalized surveillance. This reduces unnecessary procedures for the 70% of patients who may not recur.
If you are a private oncology clinic dealing with inefficient patient throughput and high costs of constant endoscopic surveillance — this project developed a risk model that identifies which patients actually need treatment. This optimizes resource allocation and improves patient satisfaction.
If you are a health insurance provider dealing with the high cost of over-treating early mucosal cancer — this project developed a cost-effectiveness analysis and health-economic model. This provides a data-driven way to reduce wasteful spending on low-risk patients.
Based on available project data, it reduces costs by preventing over-treatment of the majority of patients through a risk stratification model that identifies who truly needs frequent surveillance.
Based on available project data, the project is currently in the pilot and randomized controlled trial phase, meaning it is not yet at full industrial scale.
Based on available project data, there is no specific mention of patents or licensing terms; the project is currently focused on validating the biomarker model.
The project runs from 2024-01-01 to 2028-12-31, indicating a 5-year development and validation cycle.
It integrates via minimally invasive cell collection (endoscopic brush cytology) and e-clinical tools to guide physician decision-making.
The consortium is research-heavy with 7 universities and 2 research institutes, but includes 2 industrial partners (15% industry ratio). With 13 partners across 9 European countries, the project has strong clinical validation capacity across 10 European clinical sites, ensuring the resulting risk model is applicable across different healthcare systems.
Contact Universiteit Antwerpen regarding the biomarker-based risk stratification model.
Contact us to identify potential licensing opportunities for the risk stratification tools.
